Association of HER2/neu single nucleotide polymorphism with trastuzumab-related cardiotoxicity in patients with breast cancer

Trial Profile

Association of HER2/neu single nucleotide polymorphism with trastuzumab-related cardiotoxicity in patients with breast cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2014

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Nov 2014 Title is not official; location and phase is assumed.
    • 17 Nov 2014 New trial record
    • 01 Mar 2013 Recruitment completed, according to 36th Annual San Antonio Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top